Hypothesis

In healthy aging, increased astrocytic monoamine oxidase B (MAO‑B) activity elevates hippocampal and striatal hydrogen peroxide, which oxidatively modifies the dopamine transporter (DAT) at cysteine residues, reducing its surface expression and altering vesicular release probability. This shifts dopaminergic signaling from phasic burst‑dependent release to elevated tonic extracellular dopamine, driving the observed inversion of the midbrain dopamine synthesis–prefrontal reward activity relationship and contributing to working‑memory decline.

Mechanistic Rationale

1. DAT Oxidative Sensitivity – DAT contains extracellular cysteines vulnerable to H₂O₂‑mediated disulfide formation, which decreases Vmax and increases Km for dopamine uptake (see structural studies of oxidative DAT inhibition)【1†L1-L3】.
2. Astrocytic MAO‑B Rise with Age – PET and post‑mortem data show a ~30 % increase in MAO‑B binding in the basal ganglia of adults >60 years, paralleling DAT loss【2†L1-L4】.
3. Tonic vs. Phasic Balance – Reduced DAT clearance prolongs extracellular dopamine, favoring tonic D2 receptor activation that shifts prefrontal neurons down the inverted‑U curve, while phasic signals needed for reward prediction are attenuated【3†L1-L3】.
4. Genetic Modulation – Individuals with the DAT 9/9 VNTR (higher baseline DAT) or DRD2 C957T CC (higher extrastriatal D2) retain more surface DAT despite oxidative stress, preserving phasic signaling and explaining their cognitive advantage in older adults【4†L1-L3】.

Testable Predictions

• Prediction 1: In adults aged 60‑75, PET‑measured MAO‑B binding will negatively correlate with DAT surface availability (via [¹¹C]PE2I) and positively with the slope of the midbrain dopamine synthesis–prefrontal activity relationship (i.e., more MAO‑B → more negative slope).
• Prediction 2: Pharmacological inhibition of MAO‑B (e.g., with safinamide) for 8 weeks will increase DAT surface binding, restore a positive midbrain‑prefrontal correlation, and improve working‑memory performance (n‑back) relative to placebo.
• Prediction 3: The cognitive benefit of MAO‑B inhibition will be greatest in carriers of the DAT 9/9 VNTR and DRD2 C957T CC genotype, reflecting a gene‑by‑treatment interaction.

Experimental Approach

1. Cohort: Recruit 120 healthy adults aged 60‑75, stratify by DAT VNTR and DRD2 C957T genotype.
2. Baseline: Acquire [¹¹C]PE2I PET for DAT, [¹¹C]DENADO PET for MAO‑B, [¹⁸F]FDOPA PET for midbrain synthesis, and fMRI during a monetary incentive delay task to quantify prefrontal reward activity.
3. Intervention: Randomized, double‑blind, placebo‑controlled trial of safinamide (50 mg/day) vs. matching placebo for 8 weeks.
4. Outcomes: Repeat PET/fMRI and cognitive battery (working memory, processing speed) post‑treatment; compute change in DAT binding, MAO‑B binding, midbrain‑prefrontal correlation slope, and working‑memory scores.
5. Analysis: Use mixed‑effects models to test predictions, incorporating genotype as moderator; mediation analysis to assess whether DAT changes mediate the effect of MAO‑B inhibition on the correlation slope and cognition.

Potential Implications

If confirmed, this hypothesis would reposition astrocytic MAO‑B as a upstream regulator of age‑related dopaminergic dysfunction, offering a biomarker‑driven, genotype‑stratified therapeutic avenue to preserve phasic dopamine signaling and mitigate cognitive decline. It also reconciles the divergent trajectories of D2 receptors and DAT by linking their functional interplay through oxidative DAT modulation, a mechanism not yet explored in the aging dopamine literature.